NASDAQ: PSTVPlus Therapeutics Inc Stock
$2.12-0.11 (-4.93%)
Updated Dec 8, 2023
PSTV Price
$2.12
Fair Value Price
$2.49
Market Cap
$9.59M
52 Week Low
$0.97
52 Week High
$7.20
P/E
-0.35x
P/B
3.66x
P/S
1.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.75M
Earnings
-$15.16M
Gross Margin
100%
Operating Margin
-391.15%
Profit Margin
-404.3%
Debt to Equity
4.06
Operating Cash Flow
-$13M
Beta
1.28
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PSTV Overview
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PSTV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PSTV ($2.12) is undervalued by 14.71% relative to our estimate of its Fair Value price of $2.49 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PSTV ($2.12) is not significantly undervalued (14.71%) relative to our estimate of its Fair Value price of $2.49 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PSTV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PSTV due diligence checks available for Premium users.
Be the first to know about important PSTV news, forecast changes, insider trades & much more!
PSTV News
Valuation
PSTV fair value
Fair Value of PSTV stock based on Discounted Cash Flow (DCF)
Price
$2.12
Fair Value
$2.49
Undervalued by
14.71%
PSTV ($2.12) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PSTV ($2.12) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PSTV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PSTV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.35x
Industry
11.7x
Market
31.32x
PSTV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.66x
Industry
5.42x
PSTV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PSTV's financial health
Profit margin
Revenue
$1.2M
Net Income
-$3.2M
Profit Margin
-259.6%
PSTV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PSTV's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$13.3M
Liabilities
$10.7M
Debt to equity
4.06
PSTV's short-term assets ($11.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PSTV's short-term assets ($11.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PSTV's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PSTV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.4M
Investing
-$10.0k
Financing
$2.5M
PSTV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PSTV vs Biotech Stocks
Plus Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.